Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

Published:2010-03-04 Issue:2 Volume:15 Page:161-165
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Ono Akira,Naito Tateaki,Murakami Haruyasu,Takahashi Toshiaki,Nakamura Yukiko,Tsuya Asuka,Kaira Kyoichi,Igawa Satoshi,Shukuya Takehiro,Tamiya Akihiro,Kaira Rieko,Endo Masahiro,Yamamoto Nobuyuki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-010-0034-0.pdf

Reference14 articles.

1. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

2. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323

3. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–3013

4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

5. Kim ES, Hirsh V, Mok T et al (2008) Phase III randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST). Lancet 372:1809–1818

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial;The Oncologist;2021-09-13

2. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer;Investigational New Drugs;2020-04-03

3. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203;Lung Cancer;2020-01

4. Gimeracil/oteracil/tegafur;Reactions Weekly;2019-08

5. A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer;Journal of Thoracic Disease;2019-05